Heritage Investment Group Inc. Has $1.88 Million Position in Eli Lilly and Company (NYSE:LLY)

Heritage Investment Group Inc. lifted its stake in shares of Eli Lilly and Company (NYSE:LLY) by 3.9% during the third quarter, HoldingsChannel reports. The firm owned 2,126 shares of the company’s stock after acquiring an additional 79 shares during the quarter. Eli Lilly and Company makes up 0.4% of Heritage Investment Group Inc.’s investment portfolio, making the stock its 24th largest position. Heritage Investment Group Inc.’s holdings in Eli Lilly and Company were worth $1,884,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. boosted its stake in Eli Lilly and Company by 19.6% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 9,897 shares of the company’s stock valued at $7,699,000 after purchasing an additional 1,620 shares during the period. M&G Plc acquired a new position in Eli Lilly and Company during the first quarter valued at approximately $8,896,000. Jupiter Asset Management Ltd. lifted its position in shares of Eli Lilly and Company by 65.8% during the 1st quarter. Jupiter Asset Management Ltd. now owns 20,412 shares of the company’s stock worth $15,880,000 after buying an additional 8,101 shares during the last quarter. Acadian Asset Management LLC boosted its stake in shares of Eli Lilly and Company by 6.6% in the 1st quarter. Acadian Asset Management LLC now owns 36,897 shares of the company’s stock valued at $28,699,000 after purchasing an additional 2,289 shares in the last quarter. Finally, Patten & Patten Inc. TN boosted its position in Eli Lilly and Company by 6.7% in the first quarter. Patten & Patten Inc. TN now owns 16,686 shares of the company’s stock valued at $12,981,000 after buying an additional 1,051 shares in the last quarter. 82.53% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 900 shares of the firm’s stock in a transaction on Friday, November 8th. The stock was sold at an average price of $803.38, for a total value of $723,042.00. Following the completion of the sale, the chief accounting officer now directly owns 5,480 shares of the company’s stock, valued at $4,402,522.40. This trade represents a 14.11 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. 0.13% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on LLY shares. Redburn Atlantic upgraded shares of Eli Lilly and Company to a “hold” rating in a report on Monday, November 4th. Wolfe Research initiated coverage on Eli Lilly and Company in a research report on Friday. They set an “outperform” rating and a $1,000.00 target price on the stock. Sanford C. Bernstein assumed coverage on shares of Eli Lilly and Company in a report on Thursday, October 17th. They issued an “outperform” rating and a $1,100.00 price target for the company. Evercore ISI raised shares of Eli Lilly and Company to a “hold” rating in a research report on Thursday, September 5th. Finally, Barclays decreased their target price on Eli Lilly and Company from $1,025.00 to $975.00 and set an “overweight” rating for the company in a research report on Thursday, October 31st. Four analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $1,007.94.

Eli Lilly and Company Stock Performance

Shares of Eli Lilly and Company stock traded down $38.66 during mid-day trading on Friday, hitting $746.20. 7,334,562 shares of the stock were exchanged, compared to its average volume of 3,137,986. Eli Lilly and Company has a 12 month low of $561.65 and a 12 month high of $972.53. The company has a 50-day simple moving average of $882.65 and a 200 day simple moving average of $869.77. The company has a market capitalization of $708.38 billion, a P/E ratio of 80.64, a P/E/G ratio of 3.07 and a beta of 0.43. The company has a debt-to-equity ratio of 2.03, a quick ratio of 0.97 and a current ratio of 1.27.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Wednesday, October 30th. The company reported $1.18 EPS for the quarter, missing analysts’ consensus estimates of $1.52 by ($0.34). The business had revenue of $11.44 billion for the quarter, compared to the consensus estimate of $12.09 billion. Eli Lilly and Company had a return on equity of 71.08% and a net margin of 20.48%. The business’s revenue was up 20.4% compared to the same quarter last year. During the same quarter last year, the business posted $0.10 earnings per share. Sell-side analysts anticipate that Eli Lilly and Company will post 13.21 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Friday, November 15th will be given a dividend of $1.30 per share. The ex-dividend date is Friday, November 15th. This represents a $5.20 annualized dividend and a yield of 0.70%. Eli Lilly and Company’s payout ratio is currently 56.22%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.